EHA-SWG Scientific Meeting on Immunotherapy: The advent of CAR T cell therapy for hematologic malignancies

Dates: February 14-16, 2019
 Amsterdam, The Netherlands
Chair: H Einsele
Co-chair: M Hudecek

Organized by: 
EHA and the EHA Scientific Working Group on Immune Therapies for Hematologic Disorders

Online registration for the EHA-SWG Scientific Meeting is now open. REGISTER HERE

This SWG meeting will have a special focus on CAR T cells, a therapeutic tool that is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases. The recent approvals of the first CAR T cells treatments in Europe represents a great opportunity to fight hematologic malignancies, but also poses serious challenges given the peculiar nature of the treatment. Patients, physicians, nurses, hospitals and whole health systems need to learn how to select the right treatments, handle specific toxicities, organize treatment units and cope with the increasing costs connected with CAR T. This meeting provides the ideal context to meet these learning objectives, with speakers that will share first hand experience, including US presenters that pioneered the field. In addition, the program will include a comprehensive outlook on the current research efforts to increase CAR T cells therapies efficacy and targets, with inputs from basic researchers as well as debates involving industry delegates.

Below you can find key information and links to important details regarding registration and accommodation. There is also a wide array of sponsorship opportunities available for pharmaceutical companies. 

EHA Topics-in-Focus Immunotherapy

Topics in Focus Immunotherapy 4This EHA-SWG Scientific Meeting is part of the Topics-in-Focus (TIF) program on Immunotherapy, launched by the EHA Board at EHA23. This program is aimed at raising awareness, providing education, furthering research, and building a network of experts with the ultimate goal to improve patient care.

Target audience

The target audience is hematologists and oncologists.


This meeting will cover the following topics:

  • CAR T therapies currently tested and used in the clinics
  • Pre-clinical pipeline – novel CAR technologies and targets
  • Safety / Clinical Management of CAR-T patients
  • Optimal patient selection for treatment with CAR T
  • Industry perspective and hospital perspective in manufacturing and administering CAR T
  • Health economics and reimbursement for CAR-T

For the complete program, please click here.

Learning objectives

After attending this EHA-SWG Scientific Meeting, you should be able to:

  • select patients for currently approved CAR T therapies,
  • recognize and manage toxicities related to CAR T therapies,
  • review therapeutic areas where new CAR T therapies are being tested,
  • describe the requirements for manufacturing and administering CAR T cells, and
  • highlight novel targets and technologies for the next generation of CAR-T.

Abstract submission

Abstract submission is officially open. Participants can submit abstracts for inclusion in the program, which will be presented in the form of an oral and/or poster presentations in various time slots.

Would you like to know more about abstract submission? Click here to submit your abstract


The meeting will be held at the Novotel Amsterdam City:
Europaboulevard 10
1083 AD Amsterdam
The Netherlands

Key dates


Online registration is open. Benefit from the reduced early registration fee by registering before January 15, 2019; 23:59 CET.

Visit this page for more information on registration and to register. 

EBAH CME accreditation

EBAH accredited stamp DEF2Continuing Medical Education (CME) is widely accepted as a means to encourage individual practitioners to maintain and develop professional knowledge and skills keeping up-to-date with latest developments within the field. The meeting will be accredited by the EBAH system. Participants of this meeting are eligible to receive one Continuing Medical Education (CME) credit point for every hour of accredited activity from the EBAH system.